POWERCHINA offre un nouvel exemple de coopération Chine-Côte d’Ivoire au profit du peuple

PÉKIN, 8 décembre 2022 /PRNewswire/ — Un reportage de : CRI Online :

POWERCHINA met en œuvre les concepts de consultation approfondie, de contribution conjointe et de bénéfices partagés, avec tout son cœur et sa sincérité, en Côte d’Ivoire, un pays d’Afrique de l’Ouest éloigné de la mer. La centrale hydroélectrique de Gribo-Popoli construite par POWERCHINA fera du fleuve de Sassandra un nouveau moteur pour le développement socio-économique du pays et de ses voisins.

Ce projet contribuera à atténuer la pénurie d’électricité en Côte d’Ivoire et jouera un rôle positif dans la promotion du développement du Pool énergétique d’Afrique de l’Ouest. Parallèlement, le projet permettra d’économiser de précieuses ressources énergétiques fossiles, de réduire la pollution de l’environnement et d’atténuer la pression environnementale. En outre, il pourra également stimuler efficacement le taux d’emploi, augmenter les recettes fiscales et promouvoir le développement des industries des matériaux et des services de construction. Son exploitation apportera de plus grands avantages sociaux et économiques, jouant un rôle important dans la promotion de l’économie ivoirienne.

Actuellement, différents axes de travail sont en cours de traitement, tels que la construction de l’usine, du déversoir, du barrage, du batardeau, l’excavation de roche et la construction temporaire. Les entreprises de construction ont travaillé ardemment pour surmonter les difficultés technologiques, les conditions géologiques locales complexes, et l’épidémie, reliant les rêves des deux peuples avec la valeur de vivre en harmonie avec les différences.

Kouamo, ingénieur de projet ivoirien, a été encouragé par POWERCHINA, ses avantages à la pointe du secteur et ses riches expériences. Il a exprimé sa profonde gratitude pour la culture d’entreprise et s’est réjoui de la poursuite de la coopération dans les projets de POWERCHINA à l’avenir.

Vaccine R&D Leader Kathrin Jansen and Immunologist Kizzmekia Corbett Awarded Sabin’s Gold Medal and Rising Star Respectively

The Albert B. Sabin Gold Medal and Rising Star Award

The Sabin Vaccine Institute awarded R&D leader Dr. Kathrin Jansen the 2022 Gold Medal for her extraordinary contributions to vaccinology. Immunologist Dr. Kizzmekia Corbett received the 2022 Rising Star award for her work advancing the field of immunization.

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — The Sabin Vaccine Institute today honored two extraordinary scientists for their breakthrough vaccine research that changed the course of the COVID-19 pandemic, advanced public health, and saved countless lives. The 2022 Albert B. Sabin Gold Medal was awarded to vaccine research leader Kathrin U. Jansen, PhD, and the Rising Star to immunologist Kizzmekia Corbett, PhD.

The Gold Medal, now in its 29th year, is Sabin’s highest scientific honor, given annually to a distinguished member of the global health community who has made exceptional contributions to vaccinology or a complementary field. Past award recipients include leaders of vaccinology and vaccine advocacy such as Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege, and Myron Levine.

Dr. Jansen was selected for her nearly three decades of commitment to advancing vaccine research and development (R&D) for a range of challenging diseases from COVID-19 to HPV and pneumonia, all of which afflict adults and children in low-and middle-income countries with already fragile health care systems.

This past August, Dr. Jansen retired as the senior vice president and head of vaccine research and development at Pfizer Inc. There, Dr. Jansen led global vaccines R&D with responsibilities ranging from discovery to post-marketing commitments. In collaboration with BioNTech, Dr. Jansen spearheaded the development of a COVID-19 vaccine that would become the first FDA and WHO-authorized COVID-19 vaccine and is the first-ever approved vaccine to use an mRNA platform.

Dr. Jansen’s leadership at Pfizer also produced newer versions of a widely used pneumococcal conjugate vaccine and vaccine candidates to prevent Streptococcus pneumoniae, respiratory syncytial virus (RSV), meningococcal infections, and Group B streptococcus. Previously, she directed vaccine R&D efforts at Merck Research Laboratories and led the development of the world’s first cervical cancer vaccine. She also contributed to programs for rotavirus, mumps, measles and rubella.

“We are delighted to recognize Dr. Jansen with our Gold Medal award for her commitment to furthering vaccines and tackling tough scientific challenges in the interest of benefitting humanity and saving lives,” says Amy Finan, Sabin’s chief executive officer. “Throughout her career, she has demonstrated a unique passion for answering perplexing research questions and making bold decisions that led to impactful public health milestones.”

Dr. Jansen said she was “humbled” by the honor. “When you look at all the previous Gold Medal recipients, they are colleagues and friends that you know and have interacted and worked with for years – passionate people, all dedicated to making a healthier world.”

Sabin’s Rising Star Dr. Corbett is an assistant professor of immunology and infectious diseases at Harvard T.H. Chan School of Public Health. A viral immunologist by training, Dr. Corbett works to advance vaccine development for pandemic preparedness and to build public confidence in vaccines, particularly among communities of color facing health disparities. While at the National Institutes of Health she was a member of the team whose research on the novel coronavirus laid the groundwork for the COVID-19 Moderna vaccine – the first candidate to be tested in Phase 1 clinical trials in the U.S.

Dr. Corbett’s research has also included a universal influenza vaccine, dengue, and respiratory syncytial virus. Currently, she leads a laboratory focused on novel coronaviruses and other infectious diseases that aims to inform vaccine development against potential future pandemics. She is also a leading advocate for STEM education, health care equity, and community-based public health outreach.

“Sabin is delighted to name Dr. Corbett this year’s Rising Star,” says Finan. “Her contributions to vaccine development are matched only by her dedication to shoring up vaccine confidence, especially among skeptics. She has done incredible work explaining the scientific rigor behind vaccines and is inspiring the next generation of researchers and public health heroes.”

“It’s a really big honor for me to win this award,” says Dr. Corbett. “Having just started my career and my own lab, winning this Rising Star Award suggests that – number one – I have a long way to go but – number two – that I am capable, which is especially good to hear from my peers, mentors and other more experienced scientists.”

About the Sabin Vaccine Institute

The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Unlocking the potential of vaccines through partnership, Sabin has built a robust ecosystem of funders, innovators, implementers, practitioners, policy makers and public stakeholders to advance its vision of a future free from preventable diseases. As a non-profit with more than two decades of experience, Sabin is committed to finding solutions that last and extending the full benefits of vaccines to all people, regardless of who they are or where they live. At Sabin, we believe in the power of vaccines to change the world.

For more information, visit https://www.sabin.org/ and follow us on Twitter @sabinvaccine.

Media contact: Rajee Suri, rajee.suri@sabin.org

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8708580

Kathrin Jansen, Líder de Pesquisa e Desenvolvimento de Vacinas, e Kizzmekia Corbett, Imunologista, Premiadas com as Medalhas Gold e Rising Star da Sabin, respectivamente

WASHINGTON, Dec. 07, 2022 (GLOBE NEWSWIRE) — O Sabin Vaccine Institute homenageou hoje duas cientistas extraordinárias pelas suas pesquisas inovadoras sobre vacinas que mudaram o curso da pandemia da COVID-19, avançaram a saúde pública e salvaram inúmeras vidas. A Gold Medal Albert B. Sabin de 2022 foi concedida à líder de pesquisa de vacinas Kathrin U. Jansen, PhD, e a Rising Star à imunologista Kizzmekia Corbett, PhD.

A Gold Medal, agora no seu 29º ano, é a maior honra científica da Sabin, concedida anualmente a um membro distinto da comunidade de saúde global pelas suas contribuições excepcionais para o campo de vacinação ou complementar. Os vencedores dos prêmios anteriores incluem líderes de vacinação e defesa de vacinas como os Drs. Barney Graham, Carol Baker, Anne Gershon, Bill Foege e Myron Levine.

A Dra. Jansen foi selecionada por suas quase três décadas de compromisso com o avanço da pesquisa e desenvolvimento de vacinas (P&D) para uma série de doenças desafiadoras, desde COVID-19 até HPV e pneumonia, que afetam adultos e crianças de países de baixa e média renda com sistemas de saúde já frágeis.

Em agosto passado, a Dra. Jansen se aposentou como vice-presidente sênior e chefe de pesquisa e desenvolvimento de vacinas da Pfizer Inc, onde liderou a pesquisa e desenvolvimento de vacinas globais com responsabilidades que vão desde a descoberta até os compromissos pós-comercialização. Em colaboração com a BioNTech, a Dra. Jansen liderou o desenvolvimento da primeira vacina em uma plataforma de mRNA contra a COVID-19 a ser autorizada pela FDA e pela OMS.

A liderança da Dra. Jansen na Pfizer também resultou em versões mais recentes de uma vacina pneumocócica conjugada amplamente usada e candidatos a vacina para prevenir o Streptococcus pneumoniae, vírus sincicial respiratório (VSR), infecções meningocócicas, e o estreptococo do Grupo B. Anteriormente, ela dirigiu os esforços de pesquisa e desenvolvimento de vacinas na Merck Research Laboratories e liderou o desenvolvimento da primeira vacina contra o câncer de colo do útero do mundo. Ela também contribuiu para programas de rotavírus, caxumba, sarampo e rubéola.

“Estamos muito contentes em conceder à Dra. Jansen o nosso prêmio Gold Medal por sua dedicação à promoção das vacinas e ao enfrentamento de desafios científicos visando beneficiar a humanidade e salvar vidas”, disse Amy Finan, diretora executiva da Sabin. “Ao longo da sua carreira, ela demonstrou um entusiasmo único por responder a perguntas de pesquisa desconcertantes e tomar decisões ousadas que levaram a marcos impactantes para a saúde pública.”

A Dra. Jansen disse que se sentiu “honrada” com a premiação. “Os ganhadores anteriores da Gold Medal são colegas e amigos com os quais eu interagi e trabalho com eles há anos – pessoas entusiasmadas, dedicadas a tornar o mundo mais saudável para todos.”

A Dra. Corbett, recebedora do prêmio Rising Star da Sabin, é professora assistente de imunologia e doenças infecciosas da Harvard T.H. Chan School of Public Health. Imunologista viral, a Dra. Corbett trabalha para promover o desenvolvimento de vacinas em antecipação às pandemias e para aumentar a confiança do público nas vacinas, particularmente entre comunidades de pessoas de cor que enfrentam disparidades de saúde. No National Institutes of Health ela foi membro da equipe cuja pesquisa sobre o novo coronavírus lançou as bases para a vacina COVID-19 Moderna – a primeira candidata a ser testada em ensaios clínicos de Fase 1 nos EUA.

A pesquisa da Dra. Corbett também incluiu uma vacina universal contra a gripe, dengue e vírus sincicial respiratório. Atualmente ela lidera um laboratório focado nos novos coronavírus e outras doenças infecciosas, visando informar o desenvolvimento de vacinas contra possíveis pandemias futuras. Ela também é uma das principais defensoras da educação STEM, da equidade nos cuidados de saúde, e do alcance da saúde pública nas comunidades.

“A Sabin tem o prazer de premiar a Dra. Corbett com o Rising Star deste ano”, disse Finan. “Sua contribuição para o desenvolvimento da vacina acompanha sua dedicação em aumentar a confiança nas vacinas, especialmente entre os céticos. Ela fez um trabalho incrível explicando o rigor científico por trás das vacinas, inspirando a próxima geração de pesquisadores e heróis da saúde pública.”

“É uma grande honra para mim ganhar este prêmio”, disse a Dra. Corbett. “O recebimento deste Prêmio Rising Star no início da minha carreira no meu próprio laboratório sugere que – primeiro – tenho um longo caminho a percorrer, mas – segundo– que sou capaz. E isso é especialmente bom de ouvir dos meus colegas, mentores e outros cientistas mais experientes.”

Sobre o Sabin Vaccine Institute

O Sabin Vaccine Institute é um dos principais defensores da expansão do acesso e uso de vacinas em todo o mundo, do avanço da pesquisa e desenvolvimento de vacinas e da ampliação do conhecimento e inovação das vacinas. Revelando o potencial das vacinas através da parceria, o Sabin criou um ecossistema robusto de financiadores, inovadores, implementadores, profissionais, formuladores de políticas e partes interessadas públicas para avançar sua visão de um futuro livre de doenças evitáveis. Como uma organização sem fins lucrativos com mais de duas décadas de experiência, o Sabin está empenhado em encontrar soluções duradouras que levem todos os benefícios das vacinas a todas as pessoas, independentemente de quem sejam ou de onde vivem. No Sabin, acreditamos no poder das vacinas para mudar o mundo.

Para mais informação, visite https://www.sabin.org/ e siga-nos no Twitter @SabinVaccine.

Contato com a Mídia: Rajee Suri, rajee.suri@sabin.org

Foto deste comunicado disponível em: https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489

La leader en recherche et développement de vaccins Kathrin Jansen et l’immunologue Kizzmekia Corbett se voient remettre respectivement la Médaille d’or et le prix Rising Star de Sabin

WASHINGTON, 07 déc. 2022 (GLOBE NEWSWIRE) — Le Sabin Vaccine Institute a récompensé aujourd’hui deux scientifiques extraordinaires pour leurs recherches de pointe en matière de vaccins qui ont permis de changer le cours de la pandémie de COVID-19, de faire progresser la santé publique et de sauver d’innombrables vies. La Médaille d’or Albert B. Sabin 2022 a été décernée à la leader de la recherche en vaccins Kathrin U. Jansen, PhD, tandis que le prix Rising Star (étoile montante) a été attribué à l’immunologue Kizzmekia Corbett, PhD.

La Médaille d’or, qui en est à sa 29e édition, est le plus prestigieux honneur scientifique de Sabin, décerné chaque année à un membre distingué de la communauté mondiale de la santé qui a apporté des contributions exceptionnelles à la vaccinologie ou à un domaine complémentaire. Les anciens lauréats incluent des chefs de file dans les domaines de la vaccinologie et de la sensibilisation aux vaccins tels que les Drs Barney Graham, Carol Baker, Anne Gershon, Bill Foege et Myron Levine.

La Dr Jansen a été sélectionnée pour ses près de 30 ans d’engagement à faire avancer la recherche et le développement (R&D) en matière de vaccins pour diverses maladies difficiles à traiter, de la COVID-19 au HPV en passant par la pneumonie, toutes susceptibles de toucher les adultes comme les enfants dans les pays à revenus faibles et modérés aux systèmes de santé déjà fragiles.

Au mois d’août passé, la Dr Jansen a quitté ses fonctions de vice-présidente sénior et de responsable de la recherche et du développement de vaccins chez Pfizer Inc. Dans cette entreprise, la Dr Jansen a mené une R&D en matière de vaccins à l’échelle mondiale, ses responsabilités allant de la découverte aux engagements post-marketing. En collaboration avec BioNTech, la Dr Jansen a été le fer de lance du développement d’un vaccin contre la COVID-19 qui est devenu le premier autorisé par la FDA et l’OMS, mais également le tout premier vaccin approuvé à utiliser une plateforme ARNm.

Le leadership de la Dr Jansen chez Pfizer a également permis de produire de nouvelles versions d’un vaccin et de candidats vaccins conjugués antipneumocoques largement utilisés dans le but de prévenir le pneumocoque, le virus respiratoire syncytial (VRS), les infections méningocoques et le streptocoque B. Elle dirigeait auparavant les initiatives de R&D en matière de vaccins chez Merck Research Laboratories et a conduit le développement du tout premier vaccin contre le cancer cervical au monde. Elle a aussi contribué à des programmes de lutte contre les rotavirus, les oreillons, la rougeole et la rubéole.

« Nous sommes ravis d’offrir la Médaille d’or à la Dr Jansen pour reconnaître son engagement à améliorer les vaccins et sa lutte face à des défis scientifiques difficiles, tout cela pour le bien de l’humanité et pour sauver des vies », a déclaré Amy Finan, présidente-directrice générale de Sabin. « Tout au long de sa carrière, elle a fait montre d’une passion exceptionnelle pour répondre aux questions de recherche les plus complexes et a pris des décisions audacieuses qui ont permis d’atteindre des étapes majeures révolutionnant la santé publique. »

La Dr Jansen a déclaré être « honorée » de recevoir ce prix. « Quand je regarde tous les précédents lauréats de la Médaille d’or, je ne vois que des collègues et amis avec qui j’ai parlé et travaillé pendant des années : des gens passionnés, voulant tous œuvrer pour un monde en meilleure santé. »

La Dr Corbett, qui a remporté le prix Rising Star de Sabin, est professeure-adjointe en immunologie et maladies contagieuses à la Harvard T.H. Chan School of Public Health. Immunologue virale de formation, la Dr Corbett œuvre dans le but de faire avancer le développement de vaccins pour préparer le monde aux pandémies et pour favoriser la confiance du public à l’égard des vaccins, particulièrement dans les communautés de couleur confrontées à des disparités en matière de santé. Quand elle travaillait aux National Institutes of Health, elle était membre de l’équipe dont les recherches sur le nouveau coronavirus ont posé les bases du vaccin Moderna contre la COVID-19, le premier candidat à avoir été testé dans des essais cliniques de phase 1 aux États-Unis.

Les recherches de la Dr Corbett s’intéressaient aussi à un vaccin universel contre la grippe, la dengue et le virus respiratoire syncytial. Elle dirige actuellement un laboratoire axé sur les nouveaux coronavirus et autres maladies contagieuses dans le but d’informer le développement de vaccins face à de futures pandémies potentielles. Elle défend aussi ardemment les études STIM, l’égalité dans les soins de santé et la sensibilisation communautaire sur la santé publique.

« Sabin se réjouit de nommer la Dr Corbett pour le prix Rising Star de cette année », a déclaré Mme Finan. « Ses contributions au développement de vaccins n’ont d’égal que son dévouement à stimuler la confiance à l’égard de ceux-ci, en particulier parmi les sceptiques. Elle a réalisé un travail incroyable pour expliquer la rigueur scientifique qui se cache derrière la conception de vaccins et inspire la nouvelle génération de chercheurs et de héros de la santé publique. »

« C’est un très grand honneur pour moi de remporter ce prix », a déclaré la Dr Corbett. « Comme je viens seulement de débuter ma carrière et de lancer mon propre laboratoire, remporter ce prix Rising Star suggère que, premièrement, j’ai encore un long chemin à parcourir mais que, deuxièmement, j’en suis capable, ce qui est particulièrement agréable à entendre de la part de mes pairs, mentors et d’autres scientifiques plus expérimentés. »

À propos du Sabin Vaccine Institute

Le Sabin Vaccine Institute est l’un des principaux défenseurs de l’élargissement de l’accès aux vaccins et de leur adoption à l’échelle mondiale, de l’avancement de la recherche et du développement de vaccins et de l’amplification des connaissances et de l’innovation en matière de vaccins. Libérant le potentiel des vaccins par le partenariat, Sabin a bâtit un écosystème robuste de bailleurs de fonds, innovateurs, agents de mise en œuvre, praticiens, décideurs politiques et parties prenantes publiques pour faire avancer sa vision d’un avenir où les maladies évitables ont enfin disparu. En tant qu’organisation sans but lucratif comptant plus de deux décennies d’expérience, Sabin s’est engagée à trouver des solutions qui durent et à étendre tous les bienfaits des vaccins à l’ensemble des individus, peu importe qui ils sont et où ils résident. Chez Sabin, nous sommes convaincus que les vaccins ont le pouvoir de changer le monde.

Pour de plus amples informations, rendez-vous sur le site https://www.sabin.org/ et suivez-nous sur Twitter @sabinvaccine.

Contact auprès des médias : Rajee Suri, rajee.suri@sabin.org

Une photo accompagnant ce communiqué de presse est disponible à l’adresse : https://www.globenewswire.com/NewsRoom/AttachmentNg/66127064-3ffb-4f40-9010-7d9da33b625b

GlobeNewswire Distribution ID 8709489

South Africa’s Water Minister Mchunu visits Lesotho to fast-track Lesotho Highlands Water Project

PRETORIA— Water and Sanitation Minister, Senzo Mchunu, will on Friday undertake a visit to Maseru in the Kingdom of Lesotho with an aim to fast-track the implementation of the Lesotho Highlands Water Project (LHWP) Phase 2.

During the visit, Mchunu will meet with Minister of Natural Resources, Mohlomi Moleko, where they will deliberate on the implementation of the Phase 2 Project and matters of mutual benefit between the two countries.

The meeting will be followed by the site visits to the Polihali Dam construction and other related sites of interest within the project area.

“The LHWP entails harnessing the waters of the Orange –Senqu River in the Lesotho highlands through the construction of a series of dams and tunnels to deliver specified quantities of water to South Africa and to utilise the water delivery system to hydro-electric power in the Kingdom of Lesotho.

“The water transfer component of Phase 2 comprises an approximately 165 metres high Concrete Faced Rockfill Dam at Polihali downstream of the confluence of the Khubelu and Senqu (Orange) Rivers and an approximately 38 kilometre concrete-lined gravity tunnel connecting the Polihali reservoir to the Katse reservoir,” the department highlighted.

Phase 1 of the Lesotho Highlands Water Project included mainly the construction of Mohale Dam, which is a large rockfill dam, 32 kilometre transfer tunnel between Mohale and Katse Dams, construction of the Matsoku Diversion Weir, and a 5.7 kilometre tunnel from the Matsoku Diversion Weir to the Katse Dam.

The department explained that the system is inter connected in such a way that water may be transferred in either direction for storage in Mohale or ultimate transfer to South Africa through the Katse reservoir.

“The completion of Phase 2 of LHWP will augment the transfer of water from Kingdom of Lesotho to the Republic of South Africa from the current 780 million m3/year to 1260 million m3/year through the Integrated Vaal River System,” the department said.

The Integrated Vaal River System is the biggest in the country comprising of 14 dams with catchments in four provinces, including Free State, Northern Cape, Mpumalanga and North West.

Source: NAM NEWS NETWORK

Mchunu visits Lesotho to fast-track Lesotho Highlands Water Project

Water and Sanitation Minister, Senzo Mchunu, will on Friday undertake a visit to Maseru in the Kingdom of Lesotho with an aim to fast-track the implementation of the Lesotho Highlands Water Project (LHWP) Phase 2.

During the visit, Mchunu will meet with Minister of Natural Resources, Mohlomi Moleko, where they will deliberate on the implementation of the Phase 2 Project and matters of mutual benefit between the two countries.

The meeting will be followed by the site visits to the Polihali Dam construction and other related sites of interest within the project area.

“The LHWP entails harnessing the waters of the Orange –Senqu River in the Lesotho highlands through the construction of a series of dams and tunnels to deliver specified quantities of water to South Africa and to utilise the water delivery system to hydro-electric power in the Kingdom of Lesotho.

“The water transfer component of Phase 2 comprises an approximately 165 metres high Concrete Faced Rockfill Dam at Polihali downstream of the confluence of the Khubelu and Senqu (Orange) Rivers and an approximately 38 kilometre concrete-lined gravity tunnel connecting the Polihali reservoir to the Katse reservoir,” the department highlighted.

Phase 1 of the Lesotho Highlands Water Project included mainly the construction of Mohale Dam, which is a large rockfill dam, 32 kilometre transfer tunnel between Mohale and Katse Dams, construction of the Matsoku Diversion Weir, and a 5.7 kilometre tunnel from the Matsoku Diversion Weir to the Katse Dam.

The department explained that the system is inter connected in such a way that water may be transferred in either direction for storage in Mohale or ultimate transfer to South Africa through the Katse reservoir.

“The completion of Phase 2 of LHWP will augment the transfer of water from Kingdom of Lesotho to the Republic of South Africa from the current 780 million m3/year to 1260 million m3/year through the Integrated Vaal River System,” the department said.

The Integrated Vaal River System is the biggest in the country comprising of 14 dams with catchments in four provinces, including Free State, Northern Cape, Mpumalanga and North West.

Update on Mandlakazi Regional Bulk Water Supply Scheme

Meanwhile, Mchunu on Thursday held a meeting with iNkosi Zulu of Mandlakazi and the community of Esiphambanweni Village at KwaNongoma in KwaZulu-Natal, to provide an update on the Mandlakazi Regional Bulk Water Supply Scheme and its plans, since the establishment of a technical task team.

This is a follow-up meeting in the area about the scheme located in Zululand District Municipality, in between Kwa-Nongoma and Mkhuze (Mkuze) towns.

Following the Minister’s engagement with the Zululand Business Forum and His Majesty, King Misizulu Ka Zwelithini recently, a technical task team was established to conduct technical evaluation on current progress made and the delays faced by the scheme.

In terms of the plans, the village of Esiphambanweni in Kwa-Nongoma stand to benefit as early as next year under the accelerated Phase 6 of the Water Supply Scheme.

The project started in 2015 and overlaps to areas under uMkhanyakude District Municipality.

The department said the scope of the project includes upgrading the water treatment works from 10 millilitre to 30 millilitre per day, laying-up of bulk main pipelines for over 30 kilometres, and the construction of various reservoirs and pump stations.

Source: South African Government News Agency

Minister Fikile Mbalula: 2022 Festive Season Road Safety Campaign

Speaking notes for the Minister of Transport, Mr Fikile Mbalula, on the occasion of the 2022 Festive Season Road Safety Campaign launch held at Heidelberg Weighbridge, Ekurhuleni On 8 December 2022 At 13h00

Director-General of the Department, Adv James Mlawu;

CEO of the RTMC, Adv Makhosini Msibi;

Acting CEO of SANRAL, Ms Lehlohonolo Pitse;

Ladies and gentlemen

Today we mark the start of the 2022 Festive Season Road Safety Arrive Alive Campaign, following two years of various levels of restrictions brought about by the COVID- 19 pandemic. This year marks the first year of normal activity since the declaration of the state of national disaster due to the COVID-19 pandemic in 2020.

This is a period when families get together, schools are closed, and many workers are on a Christmas break and everyone partakes in the festivities of the season. It is a time to relax, recharge and take a well-deserved break from a challenging year. It is equally a period where many revelers take to the roads having had one too many while others conduct themselves recklessly placing the lives of other road users at risk.

This is also a period when migrant workers make their way home away from the cities where they earn a living, crossing Provincial and national boundaries, resulting in congested roads. This places tremendous pressure on our roads and requires heightened law enforcement to ensure that every road user reaches their destination alive.

This congestion across our national road network requires of the road users to exercise extreme caution and vigilance. Road crashes resulting in serious injuries and fatalities continue to pose a huge burden to our economy, with a loss of more than R188 billion annually.

Historic trends demonstrate that the festive season is characterized by lawlessness on our roads. This is a consequence of those who conduct themselves in a manner that undermines the rights of others to use the shared roadspace. This is conduct that often results in the loss of life and limb on the roads.

We remain resolute in our efforts to arrest the carnage on our roads. It is of paramount importance that we tackle the drivers of fatalities on the road.

It is estimated that more than 90% of road traffic crashes can be directly attributed to the human element, which invariably relate to violation of traffic rules.

Today we are launching the 2022 Road Safety Arrive Alive Campaign under the theme “It Starts with You”. This is to emphasise that road safety is a collective responsibility.

If we are to achieve our target of reduce carnage on our roads by 25% by 31 March 2024, road users must change their behaviour and attitude. Law enforcers must do their work without fear or favour and road authorities must create a conductive environment to improve safety on the roads.

However, we all know that the festive season is called a silly season because this is the period in which people exhibit their worst behaviour. It is this phenomenon that we intend to uproot and throw a book at those who continue to break the law with impunity. Reckless behaviour that places the safety of others in harm’s way will not go unpunished and the consequences will be dire.

We must all remember that there is life beyond December. Beyond December children must go to school, workers must get back to the task of enabling economic productivity, and life’s ambitions must be fulfilled. That is why we remind people to live beyond December.

The Road Traffic Management Corporation (RTMC) has packaged a comprehensive plan towards tackling ill- discipline that drives fatalities on our roads. As we implement our festive season law enforcement interventions, we will tighten the noose around the necks of those who continue to perpetuate unlawful conduct.

All traffic law enforcement authorities across spheres of government, have committed themselves to aggressively tackle the following priority areas:

• Vehicle roadworthiness

• Pedestrian safety

• Public passenger Transport

• Drunken driving

• Speeding

All vehicle fitness aspects will be closely monitored with intensified emphasis on passenger-carrying vehicles such as minibus taxis, buses and bakkies. All transgressions will be addressed and prioritised accordingly, and offenders will meet with the full might of the law.

The interventions that we initiated on the N2 Pongola and N3 Pietermaritzburg, including the routes R34 and R66 to address truck crash will be intensified. We are pleased that the National Prosecuting Authority (NPA) has dedicated prosecutors, who will direct investigations of all truck and bus crashes on these routes.

Multi-disciplinary law enforcement operations will be conducted over the festive season to stop and check trucks and buses for roadworthiness on these routes as part of a nation-wide operation. Traffic authorities will also use the automatic number plate recognition technology to determine if trucks and buses travelling on the identified routes comply with road regulations.

Vehicles travelling without registration plates or permits will be prosecuted. Special targeted alcohol enforcement roadblocks will be carried out at high-risk areas and motorists are warned that should they be found with a blood alcohol level over the legal limit, the law will take its full course.

A stern warning must go to those who believe they can drive under the influence of alcohol on our roads with impunity because they have the means to bribe law enforcement officials. Our anti-corruption efforts will focus on these wayward motorists and those law enforcement officials who either accept or solicit these bribes. This is a cancer we are determined to uproot if we are to make a telling difference in making our roads safer.

This year, our traffic law enforcement has been given a boost with the deployment of new technology, called the e- force. The National Traffic Police has piloted this technology over the past few months and has held extensive engagements with prosecution authorities to enable its use in traffic management. The e-force will enable our officers to prosecute more traffic offenders, as it enables them to identify drivers and ownership of vehicles by simply scanning the drivers’ licenses and vehicle discs. Minimum effort and maximum results. Those who driver around with vehicle discs obtained fraudulently will be apprehended.

Through the RTMC’s national anti-corruption unit we have built institutional capacity to deal with bribery, fraud, and corruption in traffic management across spheres of government. The anti-corruption unit will be deployed to ensure that corruption by both law enforcement officers, and motorists does not undermine our efforts. We will only succeed if motorists and the broader civil society work with us in unearthing corruption in the traffic environment.

To our men and women in uniform, the task of saving life and limb and ensuring our roads are safe is an important national service you must undertake with diligence and pride. This is an immense contribution not only to ensuring that the economy thrives, but also to saving lives that have so much to contribute to society. We salute your efforts and will provide the necessary support to ensure that you have the necessary tools of trade to do your work to the best of your ability.

To all road users who rely on our roads for their livelihood and to connect with family and loved ones, I appeal that you to exercise care and patience on the road and appreciate that the road is a shared space. Be patient at the various enforcement interventions and remember these officers are out there doing a thankless task, exposed to the elements just to ensure your safety. Saving life and limb this festive season depends on your conduct and respect for the rights of others using the road. We must all appreciate that road safety is everyone's responsibility. It starts with you.

I wish to conclude with a special appeal to motorists. Please drive with your headlights on during the day to enhance visibility. Please plan your trips carefully and avoid travelling at night or early hours of the morning as these are times when most crashes occur. Reduce your speed when driving in rainy conditions. Be always on the lookout for pedestrians.

I also wish to thank the private sector partners who continue to support our road safety efforts throughout the year.

We are in this together. Working together, we can make a telling difference in saving life and limb on our roads and grow South Africa. Buckle up and let us all Arrive Alive.

I thank you.

Source: Government of South Africa